CRO Services
Drug Development Expertise Empowering Research Services for Biologics

Early-stage biologics discovery often prioritizes binding affinity but overlooks critical developability factors, leading to CMC and clinical challenges. This webinar introduces the Micro Developability platform, a high-throughput analytical suite that requires <1 mg of antibody per assay to assess key developability attributes like sequence liability, PK and stability. Through case studies, we will illustrate how these early assessments optimize leads, mitigate downstream risks, and facilitate a smooth transition to CMC.

You will gain valuable insight into:

◇ High-throughput assays with robust performance and high sensitivity for biophysical and PK profiling, including AC-SINS, BVP/DNA/insulin ELISA, FcRn affinity and serum stability

◇ Integrated developability assessments combining in silico modeling and in vitro assays to identify potential risks in early stage

◇ Micro-developability strategy for new modalities

Webinar Details

Date: Tuesday, February 27, 2025

Time: 8:00 AM PT | 11:00 AM ET | 4:00 PM GMT

Speaker:

Lei Guo, Ph.D.

Senior Director, CRO Services

Dr. Lei Guo leads the Protein Analytical Chemistry group in WuXi Biologics CRO Services Department. Her team specializes in comprehensive analytical testing of monoclonal antibodies, bispecific antibodies, ADCs, and fusion proteins in drug discovery and optimization stages, employing Mass Spec for physicochemical and biophysical analyses. With over 14 years of experience in bioanalysis, Dr. Guo has held diverse roles at Pfizer, Sanofi, and MSD, contributing to target discovery, drug development, and CMC-stage analysis.

Enter your information to watch the recording

Have specific questions about early-stage developability assessment?

Reach out to our experts!